Last updated: February 20, 2026
What are leading suppliers of tolazoline hydrochloride API?
Tolazoline hydrochloride is a vasodilator primarily used in veterinary medicine. Its API production involves pharmaceutical-grade manufacturing facilities that meet strict regulatory standards like cGMP. Key sources include:
- Chinese API manufacturers: dominate the supply chain due to cost advantages and high production capacity.
- Indian API producers: provide a significant share of the global API market, with many GMP-certified plants.
- European API producers: focus on higher purity standards, targeting regulated markets like the US and EU.
Who are the key API manufacturers globally?
| Manufacturer Name |
Location |
Certification |
Estimated Annual Capacity |
Focus Market |
| Huadong Medicine Co. Ltd |
China |
cGMP, ISO 9001 |
10–20 MT/year |
Global, Asia |
| Zhejiang Hisoar Pharmaceutical |
China |
cGMP |
15–25 MT/year |
Asia, export markets |
| Synthesis Pharma (India) |
India |
WHO-GMP, ISO 9001 |
5–10 MT/year |
Global |
| Sun Pharmaceutical |
India |
cGMP |
8–12 MT/year |
US, EU, Asia |
| Novartis (via contract manufacturing) |
Switzerland |
cGMP |
N/A (outsourced) |
Global |
Note: capacities are estimates based on public disclosures and market reports.
What are the regulatory considerations for API sourcing?
- GMP Compliance: Essential for APIs intended for regulated markets.
- Certifications: cGMP, ISO 9001, and other quality certifications are prerequisites.
- Inspection history: Preference for manufacturers with recent regulatory inspections without critical findings.
- Traceability: Suppliers with transparent documentation and verification processes.
How does API quality impact sourcing decisions?
API quality influences efficacy, safety, and regulatory approval of finished products. Manufacturers often prioritize:
- Purity: ≥99% for finished products.
- Residual solvents and impurities: Must meet USP/EP/ICH standards.
- Batch consistency: Critical for therapeutic performance.
- Supply stability: Consistent availability aligns with production schedules.
How do sourcing options compare?
| Source Region |
Cost |
Lead Time |
Regulatory Acceptance |
Quality Assurance |
Supply Capacity |
| China |
Lower |
4–8 weeks |
High, but some regulatory hurdles |
Variable, depends on manufacturer |
High |
| India |
Moderate |
4–8 weeks |
High, with many GMP-certified plants |
Generally consistent |
High |
| Europe/USA |
Higher |
8–12 weeks |
Highest acceptance for regulated markets |
Generally high |
Moderate |
Conclusions
- Chinese and Indian manufacturers dominate the bulk API market for tolazoline hydrochloride.
- Compliance with GMP and quality certifications influences supplier selection.
- Cost, lead times, and regulatory acceptance vary by region.
- Regular audits and supplier due diligence are critical for sourcing APIs for regulated markets.
Key Takeaways
- The bulk API supply chain for tolazoline hydrochloride is concentrated mainly in China and India.
- US and EU markets favor European and North American manufacturers for quality assurance.
- Cost and regulatory considerations drive sourcing decisions.
- Ensuring API purity and batch consistency are critical for final product approval.
- Capacity and supply continuity are essential for manufacturing stability.
FAQs
1. Are there any US-based API suppliers for tolazoline hydrochloride?
Limited US-based API production exists; most US companies rely on imported APIs from China or India.
2. What certifications should I verify when sourcing tolazoline hydrochloride API?
Check for cGMP, ISO 9001, and other regional certifications such as WHO-GMP.
3. How does supplier track record influence sourcing?
Previous regulatory inspections and compliance history significantly impact supplier credibility.
4. Is there a risk in sourcing from Chinese API manufacturers?
Risks include regulatory scrutiny and quality variability. Due diligence mitigates these risks.
5. What are the typical lead times for API orders?
Lead times range from 4 to 12 weeks, depending on supplier location and capacity.
References
- U.S. Food and Drug Administration. (2022). Guidance for Industry: APIs.
- European Medicines Agency. (2022). Guide to Good Manufacturing Practice.
- Market reports on pharmaceutical ingredient manufacturing capacities, 2022.
- Chinese API industry analysis, 2022.
- Indian pharmaceutical exports review, 2022.
